Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (404)	1/3/1999 12:27:00 AM
From: poodle	Read Replies (2) \| Respond to of 4474

Martin, Results are very good. Extremely important step for gene therapy - regulation in primates by small drug molecule. Important for ARIA also. Their ideas and hard work have been proven to be successful. Artificial system of gene expression regulation does work in monkeys! But... I see a lot of excitement around. If my memory is correct, it's an old news, at least partially. Also, there are some very important facts to consider. 1.Rapamycin is potent immunosuppresant, so it's potential as small molecule drug for gene expression regulation is very limited. Looks like work with another molecule is already on it's way, but I should check. 2. As it was shown for many other gne therapy experiments, effect is short term. For monkeys it was 3 months. From this Science paper:"The peak induction of recombinant Epo was decreased 20-fold at 3 months and became indistinguishable from endogenous Epo after 4 months." I still believe that much more complicated systems have to be designed for gene therapy and that ex-vivo therapy may be more successful at this stage. In any case, it was nice to see very good news at the 1st day of new year. Well, someone had time to look at it last year, but that's their problems and gains. <g>